Aclaris Therapeutics, Inc. ACRS · NASDAQ
$3.97 -0.63% (-$0.03)
Summary
28 / 100 · Bulios Score
What speaks for it
- It has no debt and holds $19.2M in cash.
What to watch
- Revenue fell by 36% a year over the last 3 years.
- The company made a loss over the last 12 months.
- Analysts expect revenue to fall by 21% this fiscal year.
- It passes only 2 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 3.8% a year over 5 years. Over the last 3 years it fell by 36% a year. For the next fiscal year analysts expect revenue to fall by 21%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $75.7M.
Profitability in detailIs it financially healthy?
YesIt has no debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 13
- Hold 3
- Sell 0
Today's price within the analysts' price targets
The average target of $10.6 is 167% above today's price. 81% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- License and Service 76%
- Contract research 24%
By region
The company reports no revenue by region.
License and Service brings in 76% of revenue.
Segments in detail